Kesimpta's complicated developmental path has shaped Genmab's approach to partnerships
Much can be learned from Kesimpta's path from disappointing cancer treatment to promising sclerosis medication, according to Genmab's CEO Jan van de Winkel – even if this has led to some frustration along the way.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Having already received approvals in the US and Europe, Novartis is currently rolling out the sclerosis drug ofatumumab in what looks like it will be a highly successful year on the market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab drug becomes more accessible in the US
For subscribers
